Cargando…

Concordance between PIK3CA mutations in endoscopic biopsy and surgically resected specimens of esophageal squamous cell carcinoma

BACKGROUND: PIK3CA mutations are expected to be potential therapeutic targets for esophageal squamous cell carcinoma (ESCC). We aimed to clarify the concordance between PIK3CA mutations detected in endoscopic biopsy specimens and corresponding surgically resected specimens. METHODS: We examined five...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hatogai, Ken, Fujii, Satoshi, Kojima, Takashi, Daiko, Hiroyuki, Doi, Toshihiko, Ohtsu, Atsushi, Ochiai, Atsushi, Takiguchi, Yuichi, Yoshino, Takayuki
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2017
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5220610/ https://www.ncbi.nlm.nih.gov/pubmed/28068934 http://dx.doi.org/10.1186/s12885-016-3041-3

Ejemplares similares

Comprehensive immunohistochemical analysis of tumor microenvironment immune status in esophageal squamous cell carcinoma
por: Hatogai, Ken, et al.
Publicado: (2016)

Relationship between the immune microenvironment of different locations in a primary tumour and clinical outcomes of oesophageal squamous cell carcinoma
por: Hatogai, Ken, et al.
Publicado: (2019)

Local efficacy and survival outcome of salvage endoscopic therapy for local recurrent lesions after definitive chemoradiotherapy for esophageal cancer
por: Hatogai, Ken, et al.
Publicado: (2016)

A retrospective observational study of clinicopathological features of KRAS, NRAS, BRAF and PIK3CA mutations in Japanese patients with metastatic colorectal cancer
por: Kawazoe, Akihito, et al.
Publicado: (2015)

Pathological tumor regression grade of metastatic tumors in lymph node predicts prognosis in esophageal cancer patients
por: Kadota, Tomohiro, et al.
Publicado: (2018)

Simultaneous identification of 36 mutations in KRAS codons 61and 146, BRAF, NRAS, and PIK3CA in a single reaction by multiplex assay kit
por: Bando, Hideaki, et al.
Publicado: (2013)

A Phase I study of intravenous PI3K inhibitor copanlisib in Japanese patients with advanced or refractory solid tumors
por: Doi, Toshihiko, et al.
Publicado: (2016)

Concordance of the Histopathologic Diagnosis of Concurrent Duodenal and Ileal Biopsy Specimens in Dogs
por: Caulfield, Sarah, et al.
Publicado: (2021)

Effect of food on the pharmacokinetics of TAS‐102 and its efficacy and safety in patients with advanced solid tumors
por: Yoshino, Takayuki, et al.
Publicado: (2016)

A retrospective study of the safety and efficacy of paclitaxel plus ramucirumab in patients with advanced or recurrent gastric cancer with ascites
por: Matsumoto, Hiroshi, et al.
Publicado: (2018)

HER2 testing on core needle biopsy specimens from primary breast cancers: interobserver reproducibility and concordance with surgically resected specimens
por: Tsuda, Hitoshi, et al.
Publicado: (2010)

Phase 1 study of trebananib (AMG 386), an angiogenesis targeting angiopoietin-1/2 antagonist, in Japanese patients with advanced solid tumors
por: Doi, Toshihiko, et al.
Publicado: (2012)

Concordance of cribriform architecture in matched prostate cancer biopsy and radical prostatectomy specimens
por: Hollemans, Eva, et al.
Publicado: (2019)

Phase II study of BKM120 in patients with advanced esophageal squamous cell carcinoma (EPOC1303)
por: Kojima, Takashi, et al.
Publicado: (2022)

Automated histological classification of whole slide images of colorectal biopsy specimens
por: Yoshida, Hiroshi, et al.
Publicado: (2017)

Analysis of PIK3CA Mutation Concordance and Frequency in Primary and Different Distant Metastatic Sites in Breast Cancer
por: Park, Jieun, et al.
Publicado: (2023)

Phase I dose-escalation study of buparlisib (BKM120), an oral pan-class I PI3K inhibitor, in Japanese patients with advanced solid tumors
por: Ando, Yuichi, et al.
Publicado: (2014)

Phase I study of TAS-102 and irinotecan combination therapy in Japanese patients with advanced colorectal cancer
por: Doi, Toshihiko, et al.
Publicado: (2015)

Preclinical efficacy of Sym004, novel anti-EGFR antibody mixture, in esophageal squamous cell carcinoma cell lines
por: Fukuoka, Shota, et al.
Publicado: (2016)

Immunotherapy for Esophageal Squamous Cell Carcinoma
por: Kojima, Takashi, et al.
Publicado: (2017)

Phase I dose-escalation study of the HSP90 inhibitor AUY922 in Japanese patients with advanced solid tumors
por: Doi, Toshihiko, et al.
Publicado: (2014)

A phase I study of intravenous aflibercept with FOLFIRI in Japanese patients with previously treated metastatic colorectal cancer
por: Yoshino, Takayuki, et al.
Publicado: (2012)

Carcinogenesis of PIK3CA
por: German, Sidra, et al.
Publicado: (2013)

Concordant analysis of KRAS, BRAF, PIK3CA mutations, and PTEN expression between primary colorectal cancer and matched metastases
por: Mao, Chen, et al.
Publicado: (2015)

Diagnostic application of PIK3CA mutation analysis in Chinese esophageal cancer patients
por: Ming, Zizhen, et al.
Publicado: (2014)

PIK3CA gene mutations in Northwest Chinese esophageal squamous cell carcinoma
por: Liu, Shi-Yuan, et al.
Publicado: (2017)

Phase 1 pharmacokinetic study of MK-0646 (dalotuzumab), an anti-insulin-like growth factor-1 receptor monoclonal antibody, in combination with cetuximab and irinotecan in Japanese patients with advanced colorectal cancer
por: Doi, Toshihiko, et al.
Publicado: (2013)

Clinicopathological and molecular features of responders to nivolumab for patients with advanced gastric cancer
por: Mishima, Saori, et al.
Publicado: (2019)

Phase 1 pharmacokinetic study of the oral pan-AKT inhibitor MK-2206 in Japanese patients with advanced solid tumors
por: Doi, Toshihiko, et al.
Publicado: (2015)

Clinical outcomes of patients with gastrointestinal stromal tumor in phase I clinical trials
por: Nagatani, Yoshiaki, et al.
Publicado: (2016)

Efficacy and safety of ramucirumab-containing chemotherapy in patients with pretreated metastatic gastric neuroendocrine carcinoma
por: Mishima, Saori, et al.
Publicado: (2018)

PIK3CA and KRAS Amplification in Esophageal Adenocarcinoma and their Impact on the Inflammatory Tumor Microenvironment and Prognosis
por: Essakly, Ahlem, et al.
Publicado: (2019)

PIK3CA in Colorectal Cancer
por: Cathomas, Gieri
Publicado: (2014)

PIK3CA exon9 mutations associate with reduced survival, and are highly concordant between matching primary tumors and metastases in endometrial cancer
por: Mjos, Siv, et al.
Publicado: (2017)

Concordance of the 21-gene assay between core needle biopsy and resection specimens in early breast cancer patients
por: Qi, Peng, et al.
Publicado: (2021)

Concordance of breast cancer biomarker testing in core needle biopsy and surgical specimens: A single institution experience
por: Slostad, Jessica A., et al.
Publicado: (2022)

Concordance between cryobiopsy and forceps biopsy specimens in assessment of immunohistochemistry staining for non-small cell lung carcinoma
por: Nishimatsu, Kanako, et al.
Publicado: (2023)

Phase 1 study of ganitumab (AMG 479), a fully human monoclonal antibody against the insulin-like growth factor receptor type I (IGF1R), in Japanese patients with advanced solid tumors
por: Murakami, Haruyasu, et al.
Publicado: (2012)

Proportion of biopsy specimens containing a tumor when compared to all biopsy specimens by transbronchial biopsy
por: Takemoto, Shinnosuke, et al.
Publicado: (2023)

Liquid biopsy: Novel perspectives on the importance and spectrum of PIK3CA, PTEN and RET mutations in solid tumors
por: Sahin, Ibrahim, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_hls9qhnred6kmrhr5sarb3rp3l